Asset Details
Do you wish to reserve the book?
Unveiling the cytotoxicity of Red Sea Moorena producens via LC-QTOF-MS/MS chemical profiling, network pharmacology, and molecular docking
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Unveiling the cytotoxicity of Red Sea Moorena producens via LC-QTOF-MS/MS chemical profiling, network pharmacology, and molecular docking
Do you wish to request the book?
Unveiling the cytotoxicity of Red Sea Moorena producens via LC-QTOF-MS/MS chemical profiling, network pharmacology, and molecular docking
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Unveiling the cytotoxicity of Red Sea Moorena producens via LC-QTOF-MS/MS chemical profiling, network pharmacology, and molecular docking
2025
Overview
Breast and liver cancers remain significant global health challenges, necessitating the discovery of novel anticancer agents. Marine cyanobacteria, such as
belonging to the family: Oscillatoriaceae, are rich sources of bioactive compounds with potential anticancer properties.
This study aims to identify and characterize bioactive compounds from
and evaluate their anticancer activity against breast and liver cancer cell lines.
was collected and authenticated using 16S rRNA sequencing. The ethanolic extract was analyzed using LC-QTOF-MS/MS to identify the potential bioactive metabolites. Network pharmacology analysis was employed to predict the potential targets of these compounds. The crude extract was fractionated, and the fractions were screened for the anticancer activity against MCF-7 and HepG2 cell lines.
LC-QTOF-MS/MS analysis identified 25 metabolites, including apocarotenoids, spirovetivane alkaloids, and toxins. Network pharmacology analysis suggested that malyngamide D, isomalyngamide I, mueggelone, 11,12-didehydrospironostoic acid, and 12-hydroxy-2-oxo-11-epi-hinesol were potential bioactive compounds targeting proto-oncogene tyrosine-protein kinase (Src), mitogen-activated protein kinase 3(MAPK3), and MAPK1 kinases. Molecular docking studies further supported these findings, with 11,12-didehydrospironostoic acid exhibiting strong binding affinities to Src and MAPK1 kinases. Among the nine fractions obtained, Fraction 1 showed the most potent anticancer activity against both MCF-7 and HepG2 cell lines, with IC
values, 59.63 ± 7.1 and 149.23 ± 0.9 µg/mL, respectively.
The results of this study highlight the potential of
as a source of novel anticancer compounds. Further investigation of the bioactive compounds in Fractions 1 and 2 may lead to the discovery of promising anticancer agents.
Publisher
Taylor & Francis Ltd,Taylor & Francis,Taylor & Francis Group
Subject
/ Antineoplastic Agents - chemistry
/ Antineoplastic Agents - isolation & purification
/ Antineoplastic Agents - pharmacology
/ Breast
/ Breast Neoplasms - drug therapy
/ Breast Neoplasms - pathology
/ breasts
/ Cancer
/ Chromatography, Liquid - methods
/ family
/ Humans
/ Kinases
/ liver
/ Liver Neoplasms - drug therapy
/ mitogen-activated protein kinase
/ Molecular Docking Simulation - methods
/ Network Pharmacology - methods
/ Red Sea
/ rRNA 16S
